Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature
Autor: | Elli V. Kostopoulou, Olga E Makri, Constantine D. Georgakopoulos, Foteini Tsapardoni |
---|---|
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
Pediatrics Retinal Disorder Thalassemia Siderophores Case Report Hemosiderosis Deferoxamine Infusions Subcutaneous Retina Drug toxicity 03 medical and health sciences 0302 clinical medicine lcsh:Ophthalmology Internal medicine Electroretinography medicine Humans Chelation therapy Dose Modification Hematology business.industry Retinal Degeneration General Medicine Middle Aged medicine.disease Pattern dystrophy Discontinuation Ophthalmology lcsh:RE1-994 030221 ophthalmology & optometry Female sense organs business Tomography Optical Coherence 030217 neurology & neurosurgery medicine.drug |
Zdroj: | BMC Ophthalmology BMC Ophthalmology, Vol 18, Iss 1, Pp 1-9 (2018) |
ISSN: | 1471-2415 |
Popis: | Background Deferoxamine (DFO) is one of the most commonly used chelation treatments for transfusional hemosiderosis. Pattern dystrophies constitute a distinct entity of retinal disorders that has been occasionally identified in association with deferoxamine. Case presentation We report two cases of bilateral macular pattern dystrophy in transfusion dependent patients undergoing chronic chelation therapy with deferoxamine due to thalassemias. Our patients were evaluated with multimodal imaging and the results are presented. Both patients had normal cone and rod responses in the full-field electroretinogram and continued the prescribed chelation therapy, after hematology consult. The patients were followed up every 3 months for 2 and 4 years respectively for possible deterioration. Their best corrected visual acuity remained stable with no anatomic change on Optical Coherence Tomography findings. Conclusion Multimodal imaging of our patients allowed a better evaluation and possibly earlier detection of the DFO-related changes. Screening and close follow up of patients under chronic chelating therapy is important in order to promptly diagnose and manage possible toxicity either with discontinuation of the offending agent or dose modification. |
Databáze: | OpenAIRE |
Externí odkaz: |